ATE58473T1 - Kombination von carbidopa/levodopa mit verzoegerter wirkstoffabgabe. - Google Patents

Kombination von carbidopa/levodopa mit verzoegerter wirkstoffabgabe.

Info

Publication number
ATE58473T1
ATE58473T1 AT87305086T AT87305086T ATE58473T1 AT E58473 T1 ATE58473 T1 AT E58473T1 AT 87305086 T AT87305086 T AT 87305086T AT 87305086 T AT87305086 T AT 87305086T AT E58473 T1 ATE58473 T1 AT E58473T1
Authority
AT
Austria
Prior art keywords
levodopa
carbidopa
delayed
controlled release
release carbidopa
Prior art date
Application number
AT87305086T
Other languages
English (en)
Inventor
Robert E Dempski
Donald W Nibbelink
Edward C Scholtz
Scott A Reines
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25365017&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE58473(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE58473T1 publication Critical patent/ATE58473T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AT87305086T 1986-06-16 1987-06-09 Kombination von carbidopa/levodopa mit verzoegerter wirkstoffabgabe. ATE58473T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87498886A 1986-06-16 1986-06-16
EP87305086A EP0253490B1 (de) 1986-06-16 1987-06-09 Kombination von Carbidopa/Levodopa mit verzögerter Wirkstoffabgabe

Publications (1)

Publication Number Publication Date
ATE58473T1 true ATE58473T1 (de) 1990-12-15

Family

ID=25365017

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87305086T ATE58473T1 (de) 1986-06-16 1987-06-09 Kombination von carbidopa/levodopa mit verzoegerter wirkstoffabgabe.

Country Status (17)

Country Link
EP (1) EP0253490B1 (de)
JP (1) JPS6354319A (de)
KR (1) KR950002882B1 (de)
AT (1) ATE58473T1 (de)
AU (1) AU597670B2 (de)
CY (1) CY1578A (de)
DE (1) DE3766308D1 (de)
DK (1) DK170514B1 (de)
ES (1) ES2018548B3 (de)
GR (1) GR3001102T3 (de)
HK (1) HK56191A (de)
IE (1) IE60508B1 (de)
IL (1) IL82823A (de)
NZ (1) NZ220599A (de)
PT (1) PT85049B (de)
SG (1) SG52191G (de)
ZA (1) ZA874233B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
US5095054A (en) * 1988-02-03 1992-03-10 Warner-Lambert Company Polymer compositions containing destructurized starch
IL94588A0 (en) * 1989-06-22 1991-04-15 Warner Lambert Co Polymer base blend compositions containing destructurized starch
CA2037178A1 (en) * 1990-02-28 1991-08-29 Albert Walter Brzeczko Deprenyl/l-dopa/carbidopa pharmaceutical composition
HU208495B (en) * 1990-06-27 1993-11-29 Alkaloida Vegyeszeti Gyar Process for producing retarde pharmaceutical compositions
US5624960A (en) * 1991-01-23 1997-04-29 Isis Pharma Gmbh Orally administrable drugs for the treatment of central dopamine deficiency conditions
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
DE4341156C2 (de) * 1993-12-02 1997-11-13 Wacker Chemie Gmbh Verwendung von in Wasser redispergierbaren Kunststoffdispersionspulvern als Arzneimittelträger
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
CA2216215A1 (en) * 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
US5945424A (en) * 1998-07-31 1999-08-31 G & H Associates, Inc. Treatment of periodic limb movement syndrome
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
WO2007055329A1 (ja) 2005-11-11 2007-05-18 Asahi Kasei Chemicals Corporation 徐放性固形製剤
WO2007113371A1 (en) * 2006-03-31 2007-10-11 Iprbox Oy Pharmaceutical composition and preparation method thereof
WO2009085306A1 (en) 2007-12-28 2009-07-09 Impax Laboratories, Inc. Controlled release formulations of levodopa and uses thereof
TR201204839A2 (tr) 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
CN105120853A (zh) * 2013-03-28 2015-12-02 奥米尼埃克蒂夫健康科技有限公司 类胡萝卜素的脑内神经保护作用
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10098845B2 (en) 2013-10-07 2018-10-16 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
WO2015127558A1 (en) * 2014-02-28 2015-09-03 UNIVERSITé LAVAL Methods and uses for inducing or facilitating micturition in a patient in need thereof
JP7066351B2 (ja) * 2017-08-18 2022-05-13 大原薬品工業株式会社 良好な徐放性を有する、レボドパ含有小型化錠剤
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH468192A (de) * 1964-06-19 1969-02-15 Ciba Geigy Verfahren zur Herstellung von Arzneimitteln in Perlenform
US3632739A (en) * 1969-12-29 1972-01-04 Sandoz Ag Solid sustained release pharmaceutical preparation
EP0082880B1 (de) * 1981-07-08 1986-06-11 Key Pharmaceuticals, Inc. Polymerische diffusionsmatritze propranolol enthaltend
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose

Also Published As

Publication number Publication date
CY1578A (en) 1991-12-20
PT85049B (pt) 1990-03-08
JPH0445B2 (de) 1992-01-06
EP0253490A1 (de) 1988-01-20
ES2018548B3 (es) 1991-04-16
AU597670B2 (en) 1990-06-07
GR3001102T3 (en) 1992-05-12
IE871559L (en) 1987-12-16
KR880000086A (ko) 1988-03-23
EP0253490B1 (de) 1990-11-22
NZ220599A (en) 1990-10-26
AU7422887A (en) 1987-12-17
PT85049A (en) 1987-07-01
DK302587A (da) 1987-12-17
HK56191A (en) 1991-07-26
KR950002882B1 (ko) 1995-03-28
ZA874233B (en) 1987-12-14
IL82823A0 (en) 1987-12-20
IE60508B1 (en) 1994-07-27
DE3766308D1 (de) 1991-01-03
JPS6354319A (ja) 1988-03-08
DK302587D0 (da) 1987-06-15
SG52191G (en) 1991-08-23
DK170514B1 (da) 1995-10-09
IL82823A (en) 1991-03-10

Similar Documents

Publication Publication Date Title
DE3875705D1 (de) Carbidopa-levodopa-zusammensetzung mit gesteuerter freigabe.
ATE58473T1 (de) Kombination von carbidopa/levodopa mit verzoegerter wirkstoffabgabe.
NO951592D0 (no) Fremgangsmåte for fremstilling av et transdermalt terapeutisk system
DE69414502T2 (de) Medizinische Vorrichtung zur Verabreichung von Aktivsubstanzen oder Arzneistoffen in sehr niedriger Dosis, insbesondere von homöopatischen Arzneistoffen
ATE49126T1 (de) Mittel zur transdermalen applikation von arzneistoffen.
ES2039437T5 (es) Liberacion controlada de polipeptidos macromoleculares.
DK0388306T3 (da) Farmaceutisk præparat til behandling af smerte knyttet til herpes zoster og postherpetisk neuralgi ved topisk påføring af l
ES2030026T3 (es) Sistema terapeutico transdermal, su aplicacion y procedimiento para su fabricacion.
EP0279977A3 (de) Transdermale Verabreichung von Progesteron, Östradiolestern und deren Mischungen
ATE81285T1 (de) Freisetzungssysteme fuer die kontrollierte anwendung von lhrh-analoga.
PT93430A (pt) Processo para a preparacao de um sistema terapeutico transdermico para a para a aministracao de substancias activas em fases e sua utilizacao para a administracao local ou sistemica de substancias activas
FI104151B1 (fi) Laite vaikuttavan aineen luovuttamiseksi ohjatusti
DK0612519T3 (da) Anvendelse af et calciumpræparat i et medikament til terapeutisk anvendelse på malkekøer, der lider af hypocalcaemia

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time